ImpediMed’s SOZO Platform Gains FDA Clearance for Sarcopenia Risk Assessment

FDA Clearance Opens New Clinical Use for SOZO

ImpediMed Limited (ASX:IPD) has taken a significant step in expanding the clinical reach of its SOZO Digital Health Platform by securing U.S. Food and Drug Administration 510(k) clearance for sarcopenia risk assessment. This approval positions SOZO as the only FDA-cleared bioimpedance spectroscopy (BIS) device authorised to assess patients at risk of sarcopenia, a condition characterised by accelerated muscle loss.

The clearance is especially relevant in oncology, where sarcopenia develops in roughly one in three breast cancer patients undergoing chemotherapy, often unnoticed due to limitations of current diagnostic tools. Traditional methods like dual-energy X-ray absorptiometry (DXA) and computed tomography (CT) scans are accurate but impractical for frequent monitoring, creating a gap in early detection and intervention.

Sarcopenia’s Hidden Impact in Cancer and Chronic Disease

Sarcopenia is more than muscle loss; it’s a predictor of how well patients tolerate treatments and recover. Low muscle mass correlates with higher chemotherapy toxicity and postoperative complications, yet it often remains undiagnosed until symptoms emerge. SOZO’s muscle-mass indices, derived from its established scan used for lymphedema monitoring, now provide clinicians with a practical, non-invasive tool to track muscle health over time.

Jay K. Harness, MD, a leading breast surgeon, emphasises the clinical importance: “Flagging the risk early, from a routine scan, means we can act while it’s reversible.” This capability supports timely interventions such as resistance exercise and nutritional optimisation, which can rebuild muscle and improve patient outcomes.

Technology Behind SOZO’s Assessment

SOZO utilises bioimpedance spectroscopy across 256 frequencies to differentiate intracellular and extracellular fluids, estimating lean and skeletal muscle mass with precision. Unlike single-frequency bioelectrical impedance analysis (BIA), SOZO’s full-spectrum approach offers the resolution needed for clinical decisions. The quick, non-invasive scan delivers immediate results, facilitating serial monitoring that is impractical with DXA or CT.

Research supports BIS as a high-value, radiation-free alternative for sarcopenia detection. In early breast cancer patients, BIS-detected sarcopenia more than doubled the odds of chemotherapy toxicity, highlighting the clinical value of SOZO’s new indication.

Commercial Rollout and Market Implications

ImpediMed plans to introduce the sarcopenia assessment feature in its upcoming SOZO software release (version 6.3), expected in Q2 FY27. This addition complements SOZO’s existing applications in lymphedema detection, heart failure fluid monitoring, and weight management, potentially broadening its appeal across oncology and chronic disease care pathways.

CEO Erik Anderson underscores the strategic significance: “Expanding SOZO into sarcopenia risk assessment means clinicians now have a practical way to see what’s happening inside the body, from a simple scan that fits right into their workflow.” This aligns with ImpediMed’s recent efforts to strengthen commercial momentum and expand reimbursement coverage in the US market, following capital raises and leadership hires earlier in 2026.